RachelAnnFreedmanMDMPH

Breast Cancer

Associate Professor of Medicine, Harvard Medical School; Medical Director of the Dana-Farber Cancer Care Collaborative, Medical Oncologist, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute; Clinical Researcher

Join to view full profile

Dr. Freedman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Freedman's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3800

Summary

Dr. Rachel Freedman is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital, Massachusetts General Hospital, North Shore Medical Center, Dana-Farber Cancer Institute, and Brigham and Women's Faulkner Hospital. She received her medical degree from Georgetown University School of Medicine and has been in practice 14 years. She specializes in breast cancer and hematologic oncology and is experienced in breast cancer, geriatrics, healthcare disparities, health services accessibility, and general medical oncology.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
Harvard School of Public HealthMPH, Clinical Effectiveness, 2007 - 2008
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2003 - 2006
Georgetown University School of MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2022 - Present
OH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
ME State Medical License 2022 - 2025
NH State Medical License 2023 - 2025
CT State Medical License 2022 - 2024
MA State Medical License 2005 - 2024
VT State Medical License 2022 - 2024
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

The Hurria Older PatiEnts (HOPE) With Breast Cancer Study Start of enrollment: 2011 Sep 09
Active, not recruiting
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Start of enrollment: 2012 Feb 01
Active, not recruiting
Phase 2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer Start of enrollment: 2015 May 01
Novel Social Media Intervention For Older Br CA Patients Start of enrollment: 2016 Feb 08
Completed
Not Applicable
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer Start of enrollment: 2018 Aug 22
Active, not recruiting
Phase 2
Elevate! : An Elderly Breast Cancer Cohort Study Start of enrollment: 2019 Feb 19
Recruiting
'ADVANCE' (A Pilot Trial) Start of enrollment: 2019 Mar 21
Active, not recruiting
Phase 1
Individualizing Surveillance Mammography for Older Breast Cancer Survivors Start of enrollment: 2019 May 16
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

76 citations
Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer
Jaclyn Sceneay, Gregory J. Goreczny, Kristin Wilson, Sara Morrow, Molly J. DeCristo
Cancer Discovery. 2019-01-01
31 citations
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
O. Metzger Filho, Julieta Leone, Tianyu Li, Zhenying Tan-Wasielewski, Lorenzo Trippa
Annals of Oncology. 2020-09-01
42 citations
The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis.
Hee Jeong Kim, Seonok Kim, Rachel A Freedman, Ann H Partridge
Breast. 2022-02-01

Journal Articles

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Aminah Jatoi, Antonio C Wolff, Harvey Jay Cohen, Rachel A Freedman, Gustav Magrinat, Julie Gralow, Gretchen Kimmick, Heidi D Klepin, Harold Burstein, Hyman Muss, Jeann..., Journal of the American Geriatrics Society

Press Mentions

‘Real Housewives of Miami’ Star Guerdy Abraira Reveals Breast Cancer DiagnosisMay 10th, 2023
Lime in Chelsea Set to Participate in Bakes for Breast CancerMay 4th, 2023
Black Women Should Start Breast Cancer Screening at Younger Age, Study SuggestsApril 28th, 2023
Join now to see all